Citius OncologyCTOR 10 PB Ratio is 1.74 as of Jun. 26, 2026, which is 1% below its 10-year median of 1.75. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Citius Oncology ranks better than 52.06% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Citius Oncology's share price is $0.6601. Citius Oncology's Book Value per Share for the quarter that ended in Mar. 2026 was $0.38. Hence, Citius Oncology's PB Ratio of today is 1.74.
The historical rank and industry rank for Citius Oncology's PB Ratio or its related term are showing as below:
CTOR'
s PB Ratio Range Over the Past 10 Years
Min: 0.74 Med: 1.75 Max: 2.54
Current: 1.74
During the past 4 years, Citius Oncology's highest PB Ratio was 2.54. The lowest was 0.74. And the median was 1.75.
CTOR's PB Ratio is ranked better than 52.06% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs CTOR: 1.74
During the past 12 months, Citius Oncology's average Book Value Per Share Growth Rate was -23.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Citius Oncology was 1.80% per year. The lowest was 1.80% per year. And the median was 1.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Citius Oncology PB Ratio Related Terms
Citius Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Citius Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Citius Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Citius Oncology's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Citius Oncology (CTOR) has a PB Ratio of 1.74 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Citius Oncology and its competitors. This is near median its historical median of 1.75. Over the past decade, Citius Oncology's PB Ratio has ranged from 0.74 to 2.54. According to the industry distribution chart, Citius Oncology ranks #442 out of 922 companies in the Drug Manufacturers industry, placing it in the top 47.9%.
Is Citius Oncology's PB Ratio too high?
Citius Oncology's current PB Ratio of 1.74 is near median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 2.54. The Drug Manufacturers industry median PB Ratio is 1.86. Citius Oncology's value of 1.74 is 6.2% below this industry median. Based on the distribution chart, Citius Oncology ranks #442 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's PB Ratio compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #442 out of 922 companies for PB Ratio. This puts Citius Oncology in the upper half of its industry. The industry median PB Ratio is 1.86. Citius Oncology's value of 1.74 is 6.2% below this benchmark. Historically, Citius Oncology's own PB Ratio has ranged from 0.74 to 2.54 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.86, Citius Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current PB Ratio of 1.74 is 6.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current PB Ratio is 1.74, which is near median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current PB Ratio of 1.74. The current PB Ratio is 1.74, which is near median its 10-year median of 1.75 and 6.2% below the Drug Manufacturers industry median of 1.86. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Citius Oncology (CTOR), the current PB Ratio is 1.74 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
